Program

13:50-14:00 Welcome opening remark

Chair:

Sadayoshi Ito (Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine, Sendai)

14:00-14:50 Strict blood pressure control and RAAS

Chair:

Satoshi Umemura (Japan Organaization of Occupational Health and Safety (JOHAS), Yokohama Rosai Hospital, Yokohama)

Lecture 1

The previous and new aspects of ACE2
Mitsuru Ohishi
Department of Cardiovascular Medicine and Hypertension, Kagoshima University, Kagoshima

Lecture 2

Potential novel approach via functionally selective modulation of angiotensin receptor signaling: Focus on angiotensin receptor-binding molecule ATRAP
Kouichi Tamura
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama

Co-sponsored by Astellas Pharma Inc. & Nippon Boehringer Ingelheim Co., Ltd.

14:50-15:40 RAAS in hypertension and CVD

Chair:

Yoshiyu Takeda (Department of Internal Medicine, Kanazawa University, Kanazawa)

Lecture 3

DUAL AT₁ RECEPTOR/NEPRILYSIN INHIBITION (ARNI) VS. AT₁ RECEPTOR BLOCKADE IN DIABETES
A. H. Jan Danser
Erasmus MC, Rotterdam

Lecture 4

Aldosterone and Mineralocorticoid Receptors - Physiology and Pathophysiology
John Funder
Hudson Institute of Medical Research, Victoria

Co-sponsored by Sumitomo Dainippon Pharma Co., Ltd. & Shionogi & Co., Ltd.

15:40-16:30 Afternoon Seminar: RAAS & sympathetic nervous system in hypertension

Chair:

Toshiro Fujita (The University of Tokyo, Tokyo)

 

The renin-angiotensin system and the sympathetic nervous system in the regulation of blood pressure by the brain and kidneys
Atsuhiro Ichihara
Department of Endocrinology and Hypertension, Tokyo Women’s Medical University, Tokyo

 

Mineralocorticoid receptor antagonists: update on off-target actions
Anastasia Susie Mihailidou
Northern Sydney Local Health District & Kolling Institute, New South Wales

Co-sponsored by MOCHIDA PHARMACEUTICAL CO., LTD & EA Pharma Co.,Ltd.

16:30-16:45 Coffee Break

16:50-18:10 Session-1: PRR & chymase

Chair:

Atsuhiro Ichihara (Department of Endocrinology and Hypertension, Tokyo Women’s Medical University, Tokyo)

Lecture 5

A mechanism for the generation of soluble (pro) renin receptor
Tsutomu Nakagawa
Department of Applied Life Science, Faculty of Applied Biological Sciences, Gifu University, Gifu

Lecture 6

Role of (pro)renin receptor in renal handling of Na⁺ and water
Tianxin Yang
University of Utah/Sun Yat-sen University, Salt Lake

Lecture 7

A Potential Role of the (Pro)renin Receptor in Lipid Metabolism
Xifeng Lu
Astra-Zeneca Shenzhen University Joint Institute of Nephrology, Department of physiology, Shenzhen University Health Science Center, Shenzhen University, Shenzhen

Lecture 8

Depressor Effect of Human Chymase Inhibitory Japanese Water Pepper: A Successful Translational Research from Bench to Clinical Application of Human Chymase
Hidenori Urata
Fukuoka University Chikushi Hospital, Fukuoka

18:10-19:10 Session-2: Angiotensinogen & big angiotensin

Chair:

A. H. Jan Danser (Erasmus MC, Rotterdam)

Lecture 9

The role of megalin in the generation of angiotensin II from angiotensinogen in the kidney
Akihiko Saito
Department of Applied Molecular Medicine, Niigata University, Niigata

Lecture 10

Megalin-Dependent Intrarenal Generation of Angiotensin II Induced by Podocyte Injury
Taiji Matsusaka
Tokai University School of Medicine, Kanagawa

Lecture 11

Big angiotensin-25 (Bang-25): a novel glycosylated angiotensin-related peptide isolated from human urine
Sayaka Nagata
Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Miyazaki

19:20-20:30 Poster presentation with beer & wine

Moderator:

 

P1

Kazuhiro Takahashi (Department of Endocrinology and Applied Medical Science, Tohoku University Graduate School of Medicine, Sendai)

P2

Kouichi Tamura (Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama)

P3

Shigeru Shibata (Teikyo University, Tokyo)

P4

Koichi Yamamoto (The department of general and geriatric medicine, Osaka University Graduate School of Medicine, Osaka)

P5

Masaki Mogi (Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Ehime)

P6

Rudy M. Ortiz (Molecular Cell Biology, School of Natural Sciences, University of California, Merced)

8:00-8:45 Morning Seminar: Uric Acid and CKD,CVD

Chair:

Toshiro Fujita (The University of Tokyo, Tokyo)

 

Serum Uric Acid and Urinary pH as Risk Factors of CKD and CVD
Sadayoshi Ito
Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine, Sendai

Co-sponsored by MSD K.K.

8:45-9:10 Uric acid in hypertension & CVD

Chair:

Kouichi Tamura (Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama)

Lecture 12

Role of Uric Acid as a Cardiovascular Risk in Hypertensive Patients
Takuya Tsuchihashi
Steel Memorial Yawata Hospital, Kitakyushu

Co-sponsored by TEIJIN PHARMA LIMITED

9:10-10:00 Uric acid in hypertension & RAAS

Chair:

Akihiko Saito (Department of Applied Molecular Medicine, Niigata University, Niigata)

Lecture 13

Uric acid as a risk of cardiovascular disease
Ichiro Hisatome
Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago

Lecture 14

Genomic landscape of primary aldosteronism
Maria-Christina Zennaro ^1,2,3
1 INSERM, UMRS_970, Paris Cardiovascular Research Center, Paris
² Université Paris Descartes, Sorbonne Paris Cité, Paris
³ Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, Paris

Co-sponsored by Fuji Yakuhin Co., Ltd. & Pfizer Japan Inc.

10:00-10:50 Hot topics in RAAS

Chair:

Kwan-Dun Wu (Internal Medicine, Nephrology Division, National Taiwan University Hospital, Taipei)

Lecture 15

AT₂ Receptor
Masaki Mogi
Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Ehime

Lecture 16

Role of Angiotensin 1-7 beyond cardiovascular diseases
Koichi Yamamoto
The department of general and geriatric medicine, Osaka University Graduate School of Medicine, Osaka

Co-sponsored by Takeda Pharmaceutical Company Limited

10:50-11:05 Coffee Break

11:05-11:30 RAAS and sodium

Chair:

Gian Paolo D. Rossi (Clinica dell’ Ipertensione Arteriosa - Department of Medicine, University of Padua, Padova)

Lecture 17

Regulation of mineralocorticoid receptor signaling in the kidney
Shigeru Shibata
Teikyo University, Tokyo

Co-sponsored by Novartis Pharma K.K.

11:30-12:45 Session-3: Hot topics in RAAS-2

Chair:

William E. Rainey (University of Michigan, Ann Arbor)

Lecture 18

Salt-induced activation of Rac1-MR pathway in salt-sensitive hypertension and chronic kidney disease
Toshiro Fujita
The University of Tokyo, Tokyo

Lecture 19

Clinical assessment of the renin-angiotensin-aldosterone system (RAAS) in patients at risk of secondary hypertension
Pierre-Francois Plouin
Hypertension unit, Hopital Europeen G Pompidou, Paris-5 University and Assistance Publique-Hopitaux de Paris, Paris

Lecture 20

Pathology update of CT negative aldosterone producing lesions
Hironobu Sasano
Department of Pathology, Tohoku University School of Medicine, Sendai

12:50-13:45 Luncheon Seminar: Diabetes and RAAS

Chair:

Hidenori Urata (Fukuoka University Chikushi Hospital, Fukuoka)

 

Pathogenesis of Diabetic Kidney Disease
Daisuke Koya
Kanazawa Medical University, Kanazawa

 

Treatment of Diabetic Nephropathy
Masakazu Haneda
Asahikawa Medical University, Asahikawa

Co-sponsored by Taisho Toyama Pharmaceutical Co., Ltd.

13:45-14:10 Hot topics in aldosterone-1

Chair:

Hirotaka Shibata (Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita)

Lecture 21

Two becomes three: CYP17A1 joins CYP11B1 and CYP11B2 as a key locus determining aldosterone phenotype
Scott M. MacKenzie
University of Glasgow, Glasgow

Co-sponsored by Pfizer Japan Inc.

14:10-15:00 Hot topics in aldosterone-2

Chair:

Yoshihiko Saito (First Department of Internal Medicine, Nara Medical University, Nara)

Lecture 22

Primary Aldosteronism: how to improve the case detection of the most common form of endocrine hypertension
Gian Paolo D. Rossi
Clinica dell’Ipertensione Arteriosa - Department of Medicine University of Padua, Padova

Lecture 23

Radiofrequency ablation therapy for aldosterone producing adenoma
Kei Takase
Department of Diagnostic Radiology, Tohoku University, School of Medicine, Sendai

Co-sponsored by Daiichi Sankyo Co., Ltd.

15:00-15:25 Coffee Break

15:25-17:25 Session-4: Asian research in RAAS-3

Chair:

Michael Stowasser (Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Greenslopes and Princess Alexandra Hospital, Brisbane)
John Funder (Hudson Institute of Medical Research, Victoria)

Lecture 24

Clinical prognosis and somatic mutation of aldosteronism in Taiwan
Vin-Cent Wu
National Taiwan University Hospital, Taipei

Lecture 25

Histopathological-specific mutation spectrum and proliferation rate of aldosterone-producing adenomas
Elena Aisha Binti Azizan
Department of Medicine, National University of Malaysia Medical Centre, Kuala Lumpur

Lecture 26

Metabolic signatures of corticoids and hybrid steroids from blood and adrenal-producing specimens
Man-Ho Choi
Korea Institute of science and Technology, Seoul

Lecture 27

The role of TIMP-1 in aldosterone-induce cardiac fibrosis
Yen-Hung Lin
National Taiwan University Hospital, Taipei

Lecture 28

Cardiovascular prevention and protection by the use of RAAS blockers in hypertension
Ji-Guang Wang
The Shanghai Institute of Hypertension, Shanghai

Lecture 29

Consensus Statement for the Diagnosis and Treatment of Primary Aldosteronism in Japan
Mitsuhide Naruse
NHO Kyoto Medical Center, Kyoto

17:30-17:50 Coffee Break

17:50-18:40 Session-5: Hot topics in aldosterone-3

Chair:

Scott M. Mackenzie (University of Glasgow, Glasgow)

Lecture 30

PRIMARY ALDOSTERONISM: RECENT ADVANCES IN DIAGNOSIS AND UNDERSTANDING OF PATHOPHYSIOLOGY
Michael Stowasser
Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Greenslopes and Princess Alexandra Hospitals, Brisbane

Lecture 31

PRIMARY ALDOSTERONISM: REVISITING THE ROLE OF SOMATIC GENE MUTATIONS
William E. Rainey
University of Michigan, Ann Arbor

18:40-19:55 Session-6: Hot topics in aldosterone-4

Chair:

Tetsuo Nishikawa (Japan Organaization of Occupational Health and Safety (JOHAS), Yokohama Rosai Hospital, Yokohama)

Lecture 32

Recent advances on subtype differentiation of Primary Aldosteronism
Paolo Mulatero
University of Torino, Torino

Lecture 33

Aldosterone and potassium homeostasis
Johannes Loffing
University of Zurich, Institute of Anatomy, Zurich

Lecture 34

The novel methods for diagnosis of primary aldosteronism
Fumitoshi Satoh
Division of Clinical Hypertension, Endocrinology & Metabolism, Tohoku University Graduate School of Medicine, Sendai

19:20-20:30

Moderator:

Kazuhiro Takahashi (Department of Endocrinology and Applied Medical Science, Tohoku University Graduate School of Medicine, Sendai)

P1-1

In patients with primary aldosteronism, obstructive sleep apnoea improves with treatment by adrenalectomy or medical therapy
Martin J. Wolley
University of Queensland Hypertension Research Centre, Queensland

P1-2

Hyperkalemia after surgical and medical treatment for the patients with primary aldosteronism: Analysis from the data of the WAVES-J study
Norio Wada
Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo

P1-3

Elevated plasma concentrations of soluble (pro)renin receptor in patients with obstructive sleep apnea syndrome in parallel with the disease severity
Kazuhiro Takahashi
Department of Endocrinology and Applied Medical Science, Tohoku University Graduate School of Medicine, Sendai

P1-4

Association of plasma soluble (pro)renin receptor levels with brain atrophy in a general population: the Ohasama Study
Hiroshi Suzuki
Department of Endocrinology and Applied Medical Science, Tohoku University Graduate School of Medicine, Sendai

P1-5

Serum soluble (pro)renin receptor levels in maintenance hemodialysis patients
Yoshifumi Amari ^1,2
1 Department of Medicine II, Endocrinology and Hypertension, Tokyo Women’s Medical University, Tokyo
² Moriguchi Keijinkai Hospital, Moriguchi

P1-6

The expression of (Pro)renin Receptor is upregulated in the Kidney of Dahl Salt-Sensitive Rats by High Salt Intake
Seiko Yamakoshi
Tohoku University Graduate School of Medicine, Sendai

P1-7

Insulin and glucose regulate the (pro)renin receptor-mediated VEGF production in retinal pigment epithelium cells
Koji Ohba
Tohoku University School of Medicine, Sendai

P1-8

Clinical significance of adrenal computed tomography findings in young patients with primary aldosteronism
Tatsuki Ogasawara
Department of Endocrinology, Metabolism, and Hypertension, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto

Moderator:

Kouichi Tamura (Department of Medical Science and Cardioneral Medicine, Yokohama City University Graduate School of Medicine, Yokohama)

P2-1

Novel histological classification of adrenocortical non-neoplastic lesions in CT negative primary aldosteronism
Yuto Yamazaki
Department of Pathology, Tohoku University Graduate School of Medicine, Sendai

P2-2

Bilateral aldosterone suppression and its resolution in adrenal vein sampling of patients with primary aldosteronism: Analysis of data from the WAVES-J study
Yui Shibayama
Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo

P2-3

The novel classification and genetic causes of bilateral hyperaldosteronism
Kei Omata
University of Michigan, Ann Arbor

P2-4

The AA2-Ratio: Towards Improved Screening for Primary Aldosteronism in Hypertension
Marko Poglitsch
Attoquant Diagnostics, Vienna

P2-5

Do we need dexamethasone suppression before ACTH stimulation test in primary aldoteronism?
Kosuke Inoue
Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Yokohama

P2-6

Identification of ectopic drainage veins from an aldosterone producing adenoma by use of computed tomography during arteriography
Takahisa Kawaguchi
Department of Internal Medicine, Keio University School of Medicine, Tokyo

P2-7

Adrenocorticotropic hormone (ACTH) administration improves the diagnostic performance of adrenal vein sampling for primary aldosteronism
Martin J. Wolley
University of Queensland Hypertension Research Centre, Queensland

P2-8

Reassessment of the Cosyntropin Stimulation Test in the Confirmatory Diagnosis and Subtype Classification of Primary Aldosteronism
Hironobu Umakoshi
Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto

Moderator:

Shigeru Shibata (Teikyo University, Tokyo)

P3-1

Quantitative mRNA Analysis of Thiazide Sodium Cotransporter in Urinary Exosomes from Normal Controls and Patients with Primary Aldosteronism
Aihua Wu
Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Queensland

P3-2

DNA hypo-methylation of Aldosterone synthesis (CYP11B2) in aldosterone producing adenoma, but not regulated by somatic mutations of adenoma
Yoko Yoshii
Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima

P3-3

Development of an inducible model of primary aldosteronism using DREADD technology
Matthew J. Taylor
University of Michigan, Department of Molecular and Integrative Physiology, Ann Arbor

P3-4

The activation of intrarenal renin-angiotensin-systems and oxidative stress in proximal tubular are the primary sources of renal damage in primary aldosteronism
Yoshitsugu Iwakura ^1,2
1 Tohoku University Hospital, Division of Nephrology, Endocrinology, and Vascular Medicine, Sendai
² Tohoku Medical and Pharmaceutical University Hospital, Division of Nephrology and Endocrinology, Sendai

P3-5

CYP11B1 can play a key role of the synthesis of 18-oxocortisol in aldosterone-producing adenoma
Yuta Tezuka
Department of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Hospital, Sendai

P3-6

RAGE-DNA APTAMER IMPROVES MR-ASSOCIATED PODOCYTOPATHY AND RENAL INJURY THROUGH RAC1-MEDIATED MR ACTIVATION
Kensei Taguchi
Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Fukuoka

P3-7

Possible Involvement of a Transitional Lesion between APCC and APA in Autonomous Aldosterone Production
Minae Koga
Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Yokohama

P3-8

Age accumulation of aldosterone-driving somatic mutations and aldosterone-producing cell clusters (APCC) in normal adrenal glands
Kei Omata
Department of Pathology, University of Michigan, Ann Arbor

Moderator:

Koichi Yamamoto (The department of general and geriatric medicine, Osaka University Graduate School of Medicine, Osaka)

P4-1

Frequency of hypertension in our district, Erbaa, a Black Sea district
Fatih Mehmet Cilingir
Medical Doctor, Internal Medicine, Bafra state hospital, Samsun

P4-2

Is It Resistant Hypertension?
Fatih Mehmet Cilingir
Medical Doctor, Internal Medicine, Bafra state hospital, Samsun

P4-3

Salt intake influences epigenetic regulation of CYP11B2 gene
Yoshimichi Takeda ^1,2
1 Asanogawa Hospital, Kanazawa
² Kanazawa University, Kanazawa

P4-4

In primary aldosteronism, mineralocorticoids and potassium influence abundance of the thiazide sensitive sodium-chloride cotransporter
Martin J. Wolley
University of Queensland Hypertension Research Centre, Queensland

P4-5

Impaired post-transcriptional modification for sodium channel caused cardiac electrophysiological involvements as cardio-renal association in salt sensitive hypertension of Nedd4-2 C2 KO mice
Shintaro Minegishi
Yokohama City University Graduate School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama

P4-6

The mechanism of blood pressure elevation in kidney-specific Hsd11b2 knockout mice
Kohei Ueda
Division of Clinical Epigenetics, Research Center of Advanced Science and Technology, The University of Tokyo, Tokyo

P4-7

Arterial wave form analysis in patients with primary aldosteronism
Che Wei Liao
Center of Critical Care Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu

Moderator:

Masaki Mogi (Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Ehime)

P5-1

Angiotensin Ii Upregulate Cytochrome P-450 4a Expression In Rat Kidney Through Angiotensin II Type 1 Receptor
Rong Rong
School of Rehabilitation Medicine Nanjing Medical University, Nanjing

P5-2

Hypokalemia and pendrin induction by aldosterone: role of mineralocorticoid receptor dephosphorylation
Ning Xu
Teikyo University School of Medicine, Tokyo

P5-3

Adipose tissue ATRAP (angiotensin II type 1 receptor-associated protein) prevents diet-induced visceral obesity and insulin resistance via the alternation of adipose GLUT4 expression
Kengo Azushima
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama

P5-4

Eplerenone Resistant Salt Sensitive Hypertension in Nedd4-2 C2 KO mice
Tabito Kino
Yokohama City University Graduate School of Medicine, Yokohama

P5-5

Angiotensin II and aldosterone have different roles in regulating Pendrin and NCC
Daigoro Hirohama
Division of Clinical Epigenetics, Reserch Center for Advanced Science and Technology, The University of Tokyo, Tokyo

P5-6

The Role of Mineralocorticoid receptor in angiotensin II-induced Pendrin expression at renal β-intercalated cells
Nobuhiro Ayuzawa
The Division of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo

P5-7

Effects of exercise training on renal damage and renin-angiotensin system in rat with chronic renal failure
Takahiro Nakamura
Tohoku University Graduate School of Medicine, Sendai

P5-8

Nrf2 Deficiency Alleviates Perinatal Complications due to Angiotensin II Overproduction in Pregnancy-Associated Hypertension Mice via Enhancing Placental Angiogenesis
Masahiro Nezu
Tohoku University Division of Nephrology, Endocrinology, and Vascular Medicine, Sendai

Moderator:

Rudy M. Ortiz (Molecular Cell Biology, School of Natural Sciences, University of California, Merced)

P6-1

Aldosterone excess state causes a chronic inflammation in pancreatic islet and eplerenone protects islet via GLP-1 secretion
Rieko Goto
Kumamoto University Faculty of Life Sciences Department of Metabolic Medicine, Kumamoto

P6-2

Cilnidipine decreases insulin resistance and aldosterone levels in essential hypertension
Hajime Ueshiba
Department of Internal Medicine, Toho University School of Medicine, Tokyo

P6-3

OPTIMIZATION ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME USING TWO FREE DOSED COMBINATIONS OF DRUGS
Jamol Uzokov
JSC «Republican specialized scientific-practical medical center of therapy and medical rehabilitation», Tashkent

P6-4

Mice lacking aldosterone synthase or treated with eplerenone are resistant to diet-induced obesity
Taeko Uchida
Division of clinical pharmacology and therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences & Faculty of Pharmaceutical Sciences, Sendai

P6-5

Aldosterone excess may inhibit insulin secretion-comparative study on glucose metabolism before and after adrenalectomy in primary aldosteronism
Akiko Ishida
Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Yokohama

P6-6

Dynamic Effects of GLP-1 agonist on Urinary Aldosterone Excretion and Na+ Balance in Insulin Resistant OLETF rats
Rudy M. Ortiz
Molecular Cell Biology, School of Natural Sciences, University of California, Merced

P6-7

The relationship of sleep apnea syndrome and primary aldosteronism
Yoshikiyo Ono
Division of Nephrology, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku Univesity Graduate school of medicine, Sendai